Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
Go back to Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)| (NASDAQ: DNLI) | Delayed: 14.96 -0.6 (3.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.56 | 52 Week High | $ | |||
| Open | $15.25 | 52 Week Low | $ | |||
| Day High | $15.25 | P/E | N/A | |||
| Day Low | $14.56 | EPS | $ | |||
| Volume | 1,140,532 | |||||
